Bevacizumab: all 1,786 studies that test it
Page 3 of 18. Open to participants first (285), then studies with results posted, then the rest; newest registration first within each.
- Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular CarcinomaRecruitingNCT06133062Phase 2
- The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical StudyRecruitingNCT06125080Phase 2
- BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical CancerRecruitingNCT06123884Phase 2/3
- Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline TherapyRecruitingNCT06083844Phase 2
- First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian CancerNot yet recruitingNCT06063070Phase 2
- Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.RecruitingNCT06060704Phase 2
- Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant TherapyNot yet recruitingNCT06035133Not applicable
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingNCT06031233Phase 4
- A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)RecruitingNCT06023862Phase 2
- Intraperitoneal Irinotecan With Concomitant FOLFOX and BevacizumabRecruitingNCT06003998Phase 2
- A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT05976568Phase 2/3
- Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional TherapyNot yet recruitingNCT05975463Phase 2
- XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRCRecruitingNCT05970302Phase 2
- Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural MesotheliomaRecruitingNCT05930665Phase 2
- KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid TumorsNot yet recruitingNCT05906524Phase 1/2
- A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered CancerRecruitingNCT05904457Phase 2
- HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 TrialRecruitingNCT05886465Phase 2
- TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven CriteriaNot yet recruitingNCT05883176Phase 2
- Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal CancerRecruitingNCT05854498Phase 2
- Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) PatientsRecruitingNCT05844046Phase 2
- Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.Not yet recruitingNCT05811793Not applicable
- Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal CancerRecruitingNCT05806931Phase 2
- QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRCRecruitingNCT05799820Phase 2
- Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer PatientsRecruitingNCT05797467Phase 3
- A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.Not yet recruitingNCT05792410Phase 1/2
- FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingNCT05749588Phase 2
- A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung CancerRecruitingNCT05654454Phase 3
- Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line TherapyRecruitingNCT05640830Phase 1/2
- Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) PatientsRecruitingNCT05638451Phase 2
- Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian CancerRecruitingNCT05636111Phase 1
- Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-riskRecruitingNCT05620771Phase 2
- Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular CarcinomaRecruitingNCT05616390Phase 2
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2
- Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver MetastasesRecruitingNCT05588388Phase 2
- Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver MetastasesNot yet recruitingNCT05588297Phase 2
- A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyRecruitingNCT05585281Phase 2
- Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent GlioblastomaNot yet recruitingNCT05540275Phase 2
- Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast CancerRecruitingNCT05525767Phase 4
- Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse AstrocytomaNot yet recruitingNCT05518994Phase 2
- Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse OligodendrogliomaRecruitingNCT05512351Phase 2
- Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung AdenocarcinomaRecruitingNCT05503667Phase 2
- Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse GlioblastomaNot yet recruitingNCT05502991Phase 2
- Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor PatientsRecruitingNCT05468359Phase 1/2
- Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation TherapyRecruitingNCT05468242Phase 2
- A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical CancerNot yet recruitingNCT05444374Phase 2
- Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast CancerRecruitingNCT05398861Phase 2
- PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT05341193Phase 1/2
- Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNARecruitingNCT05334277Phase 2
- Effect of Bevacizumab on Asymptomatic Radiotherapy-induced Brain InjuryRecruitingNCT05303259Phase 2
- Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent GlioblastomaRecruitingNCT05284643Not applicable
- Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung CancerRecruitingNCT05284539Phase 2
- Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBMRecruitingNCT05271240Phase 3
- Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan CriteriaEnrolling by invitationNCT05185505Phase 4
- Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course RadiotherapyRecruitingNCT05111860Phase 1/2
- Atezolizumab+Bevacizumab+SBRT in Unresectable HCCRecruitingNCT05096715Phase 1
- ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver MetastasesRecruitingNCT05062317Phase 2
- IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsRecruitingNCT05039801Phase 1
- Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian CancerRecruitingNCT05009082Phase 3
- Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanRecruitingNCT05005403Phase 1
- Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLCNot yet recruitingNCT04988607Phase 2
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerRecruitingNCT04981509Phase 2
- Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung CancerRecruitingNCT04973293Not applicable
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingNCT04929223Phase 1
- APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant EffusionRecruitingNCT04919629Phase 2
- The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular CarcinomaRecruitingNCT04803994Phase 3
- A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian CancerRecruitingNCT04787289Phase 2
- Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast CancerRecruitingNCT04739670Phase 2
- 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.RecruitingNCT04689347Phase 1/2
- Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal CancerRecruitingNCT04659382Phase 2
- A Study of Azenosertib (ZN-c3) in Patients With Ovarian CancerRecruitingNCT04516447Phase 1
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingNCT04486352Phase 1/2
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)RecruitingNCT04374305Phase 2
- Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune InfiltrateRecruitingNCT04262687Phase 2
- A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine GliomaRecruitingNCT04250064Phase 2
- Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/BevacizumabRecruitingNCT04224636Phase 2
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerRecruitingNCT04181060Phase 3
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver CancerRecruitingNCT03942328Phase 1/2
- Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2
- Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLCRecruitingNCT03872661Phase 2
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2
- Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.RecruitingNCT03401294Phase 2
- Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of RecurrenceRecruitingNCT02446431Early Phase 1
- Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma MultiformeRecruitingNCT02285959Phase 1
- Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With BevasizumabRecruitingNCT01917877Phase 2
- Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AARecruitingNCT01269853Phase 1/2
- A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)CompletedNCT06190093Phase 3Results posted
- ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal CancerTerminatedNCT05824559Phase 1Results posted
- Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCCTerminatedNCT05776875Phase 2Results posted
- Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian CancerCompletedNCT05751629Phase 2Results posted
- Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral TherapyTerminatedNCT05717400Phase 4Results posted
- Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A MutationTerminatedNCT05523440Phase 2Results posted
- Clinical Study to Evaluate PRO-169 for Diabetic Macular EdemaCompletedNCT05217680Phase 3Results posted
- A Study of Atezolizumab and Bevacizumab in Hepatocellular CarcinomaCompletedNCT04829383Phase 2Results posted
- Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT04753216Phase 2Results posted
- Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer PatientsCompletedNCT04737187Phase 3Results posted
- A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic TherapyTerminatedNCT04732286Phase 3Results posted
- A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract CancerCompletedNCT04677504Phase 2Results posted
- A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROPTerminatedNCT04634604Phase 3Results posted
- MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLCCompletedNCT04633564Phase 3Results posted
- Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMDCompletedNCT04626128Phase 1/2Results posted